All In Biotech

Drug Trial Radar · NCT03910621

Safety and Efficacy of Miglustat in Chinese NPC Patients

A Single Arm Uncontrolled 12 Months Clinical Study to Evaluate the Safety and Efficacy of Miglustat (Zavesca) for the Treatment of Niemann Pick Type C Disease (NPC) in Chinese Subjects

Last checked: Nov 20, 2026Latest source record: Mar 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

17

Actual

Start

Apr 2, 2020

Primary completion

Mar 25, 2022

Study completion Mar 25, 2022

Sponsor

Lead sponsor
ActelionJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Apr 10, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 4 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, multi-center, open-label, non-randomized, single-arm Phase IV confirmatory study. Approximately 19 subjects with Niemann Pick Type C disease (NPC) will be enrolled in this study. The study will be conducted at 2 sites in China.

Conditions

  • Niemann-Pick Disease, Type C

Interventions

  • MiglustatDrug

    capsule, oral use

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Observed change in HSEM (ms/deg)Time frame: baseline to week 52

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Peking University first Hospital

    Beijing, China

  • Xin Hua Hospital, Shanghai Jiao Tong University

    Shanghai, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.